الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 144 |  |  |
| | | from | 144 | | |
Abstract
Hepatitis c virus (HCV) infection is a major health trouble worldwide. HCV is not only the causative of kidney disease but also contributes to increase morbidity and mortality in patients with established CKD.
The current study was carried out at El-Minia governate. These observational, analytic and longitudinal study was carried out on 1433 patients with chronic kidney disease on regular haemodialysis. Participants divided into two groups according to HCV surface antibody by ELISA test.
All patients underwent a thorough clinical evaluation (full history taking, general examination and systemic examination). The laboratory tests were also carried out to all individuals including: Hepatitis C virus markers and iron profile (serum iron, serum ferritin, total iron binding capacity and transferrin saturation).
The aim of the work was to study the response of Erythropoiesis stimulating agents in hemodialysis patients with positive hepatitis C antibody compared to HCV negative patients.
Results of our study can be discussed as follows Both haemoglobin levels and haematocrit values were significantly higher in hepatitis C virus positive compared with its corresponding one from the negative group .
Transferrin saturation (T sat) and serum ferritin revealed a significant difference between chronic kidney disease patients with positive HCV markers and chronic kidney disease patients with negative HCV marker.
Conclusion
We concluded from this study that chronic kidney disease patients with positive HCV antibody tend to have higher haemoglobin and haematocrit levels than chronic kidney disease patients with negative HCV. Because the ferritin level also were high in positive than negative and consequently HCV positive patients required lower erythropoietin doses.
chronic inflammation of the liver may be the cause for increased EPO production, these needs to be clarified in further studies.